Fashioning Queer Bodies: Intersections of Dress, Identity, and Anxiety for Queer Women

The purpose of this research is to understand the relationship of dress and queer women, and how their sexual identity influences their appearance management behaviors without ignoring other subject positions such as class, race, ethnicity, location, age, and religion. Understanding queer women’s experiences with clothing is of benefit to society for promotion of equality. It is hoped this research will result in the reduction of discrimination

Searching for Clusters with SUMSS

Statistical overdensities of radiosources in the Sydney University Molonglo Sky Survey (SUMSS) are used as signposts to identify high-redshift clusters of galaxies. These potential clusters have been observed at 20 and 13 cm at the Australia Telescope Compact Array (ATCA) to obtain better positional accuracy for the sources. A subsample have been imaged in V, R and I at the 2.3-m telescope at Siding Spring and in J and K at the Anglo Australian Telescope (AAT) and the New Technology Telescope (NTT) at La Silla, Chile. The colours obtained from these observations will be used to estimate redshifts for the potential cluster members.Comment: LaTeX, 5 pages, 4 figures Elsevier Science format. To appear in "Radio galaxies: past, present & future". eds. M. Jarvis et al., Leiden, Nov 200

Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons

Alternative splicing—the production of multiple messenger RNA isoforms from a single gene—is regulated in part by RNA binding proteins. While the RBPs transformer2 alpha (Tra2α) and Tra2β have both been implicated in the regulation of alternative splicing, their relative contributions to this process are not well understood. Here we find simultaneous—but not individual—depletion of Tra2α and Tra2β induces substantial shifts in splicing of endogenous Tra2β target exons, and that both constitutive and alternative target exons are under dual Tra2α–Tra2β control. Target exons are enriched in genes associated with chromosome biology including CHEK1, which encodes a key DNA damage response protein. Dual Tra2 protein depletion reduces expression of full-length CHK1 protein, results in the accumulation of the DNA damage marker γH2AX and decreased cell viability. We conclude Tra2 proteins jointly control constitutive and alternative splicing patterns via paralog compensation to control pathways essential to the maintenance of cell viability

Community level digital mental health interventions:A policy and practice brief

The prevalence of mental ill-health is increasing worldwide and brings adverse consequences at both the individual and societal level. Treatments and interventions for the symptoms that represent mental health conditions may target biological, behavioural and cognitive factors. Traditionally, treatments have included psychotropic medication, and/or psychological therapies which are delivered on a one to one or group basis. Both have a high economic cost, and efficacy varies. In addition, help seeking behaviour is impacted by stigma, symptom recognition &amp; understanding, and a host of factors associated with the disorders themselves, such as avoidance behaviour. The delivery of face-to-face interventions for those who are most marginalised and most at risk from mental ill-health, can also be impacted by barriers, such as knowledge of the services available and time, connectivity or travel constraints. The research presented here is co-produced with service providers, end users and academic experts across the disciplines of psychology, business, medicine, healthcare, interaction design and computer science. This briefing is based on the findings from our research programme on a community level digital mental health intervention.<br/

Diet, Physical Activity and Gestational Weight Gain Patterns among Pregnant Women Living with Obesity in the North East of England: The GLOWING Pilot Trial

Maternal diet, physical activity (PA) behaviours, and gestational weight gain (GWG) are important for optimum health of women and their babies. This secondary analysis of the GLOWING pilot cluster trial explored these among women living with obesity in high deprivation. Pregnant women completed food frequency, PA and psychosocial questionnaires. Weights were retrieved from medical records and measured during routine appointments with midwives. Descriptive and regression analyses were stratified by obesity class. A total of 163 women were recruited; 54.0% had class 1 obesity, 25.8% class 2, 20.2% class 3, and 76.1% lived in the two most deprived quintiles. Women had suboptimal dietary intake, particularly for oily fish, fruit and vegetables. PA was predominantly light intensity, from household, care and occupational activities. Most women gained weight outside of Institute of Medicine (IOM) guideline recommendations (87.8%); women in class 3 obesity were most likely to have inadequate GWG below IOM recommendations (58.3%, p 0.01) and reduced odds of excessive GWG compared with class 1 (AOR 0.13, 95% 0.04–0.45). Deprived women with obesity have a double inequality as both increase pregnancy risks. This population requires support to meet guideline recommendations for diet, PA and GWG. Further research exploring obesity classes would inform policies and care to achieve the best pregnancy outcomes

Radio galaxies in the 2SLAQ Luminous Red Galaxy survey: II. The stellar populations of radio-loud and radio-quiet LRGs

We present an analysis of the optical spectra of a volume-limited sample of 375 radio galaxies at redshift 0.4<z<0.7 from the 2dF-SDSS Luminous Red Galaxy and QSO (2SLAQ) redshift survey. We investigate the evolution of the stellar populations and emission-line properties of these galaxies. By constructing composite spectra and comparing with a matched sample of radio-quiet sources from the same survey, we also investigate the effect on the galaxy of the presence of an active nucleus. The composite spectra, binned by redshift and radio luminosity, all require two components to describe them, which we interpret as an old and a younger population. We found no evolution with redshift of the age of the younger population in radio galaxies, nor were they different from the radio-quiet comparison sample. Similarly, there is no correlation with radio power, with the exception that the most powerful radio sources (P(1.4) > 10^26 W/Hz) have younger stars and stronger emission lines than the less powerful sources. This suggests that we have located the threshold in radio power where strong emission lines "switch on", at radio powers of around 10^26 W/Hz. Except for the very powerful radio galaxies, the presence of a currently-active radio AGN does not appear to be correlated with any change in the observed stellar population of a luminous red galaxy at z~0.5.Comment: 10 pages, 10 figures and 2 tables, accepted for publication in MNRA

The Australia Telescope Large Area Survey: Spectroscopic catalogue and radio luminosity functions

The Australia Telescope Large Area Survey (ATLAS) has surveyed 7 square degrees of sky around the Chandra Deep Field South and the European Large Area ISO Survey-South 1 fields at 1.4 GHz. ATLAS aims to reach a uniform sensitivity of 10 μJy beam−1 rms over the entire region with first data release currently reaching ∼ 30 μJy beam−1 rms. Here we present 466 new spectroscopic redshifts for radio sources in ATLAS as part of our optical follow-up programme. Of the 466 radio sources with new spectroscopic redshifts, 142 have star-forming optical spectra, 282 show evidence for active galactic nuclei (AGN) in their optical spectra, 10 have stellar spectra and 32 have spectra revealing redshifts, but with insufficient features to classify. We compare our spectroscopic classifications with two mid-infrared diagnostics and find them to be in broad agreement. We also construct the radio luminosity function for star-forming galaxies to z = 0.5 and for AGN to z = 0.8. The radio luminosity function for star-forming galaxies appears to be in good agreement with previous studies. The radio luminosity function for AGN appears higher than previous studies of the local AGN radio luminosity function. We explore the possibility of evolution, cosmic variance and classification techniques affecting the AGN radio luminosity function. ATLAS is a pathfinder for the forthcoming Evolution Map of the Universe (EMU) survey and the data presented in this paper will be used to guide EMU's survey design and early science papers

Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission

Abstract Admission procalcitonin measurements and microbiology results were available for 1040 hospitalized adults with coronavirus disease 2019 (from 48 902 included in the International Severe Acute Respiratory and Emerging Infections Consortium World Health Organization Clinical Characterisation Protocol UK study). Although procalcitonin was higher in bacterial coinfection, this was neither clinically significant (median [IQR], 0.33 [0.11–1.70] ng/mL vs 0.24 [0.10–0.90] ng/mL) nor diagnostically useful (area under the receiver operating characteristic curve, 0.56 [95% confidence interval, .51–.60]).</jats:p

Implementation of corticosteroids in treating COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK:prospective observational cohort study

BACKGROUND: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial publication on June 16, 2020, and to identify discrepancies in care. METHODS: We did an audit of clinical implementation of corticosteroids in a prospective, observational, cohort study in 237 UK acute care hospitals between March 16, 2020, and April 14, 2021, restricted to patients aged 18 years or older with proven or high likelihood of COVID-19, who received supplementary oxygen. The primary outcome was administration of dexamethasone, prednisolone, hydrocortisone, or methylprednisolone. This study is registered with ISRCTN, ISRCTN66726260. FINDINGS: Between June 17, 2020, and April 14, 2021, 47 795 (75·2%) of 63 525 of patients on supplementary oxygen received corticosteroids, higher among patients requiring critical care than in those who received ward care (11 185 [86·6%] of 12 909 vs 36 415 [72·4%] of 50 278). Patients 50 years or older were significantly less likely to receive corticosteroids than those younger than 50 years (adjusted odds ratio 0·79 [95% CI 0·70–0·89], p=0·0001, for 70–79 years; 0·52 [0·46–0·58], p80 years), independent of patient demographics and illness severity. 84 (54·2%) of 155 pregnant women received corticosteroids. Rates of corticosteroid administration increased from 27·5% in the week before June 16, 2020, to 75–80% in January, 2021. INTERPRETATION: Implementation of corticosteroids into clinical practice in the UK for patients with COVID-19 has been successful, but not universal. Patients older than 70 years, independent of illness severity, chronic neurological disease, and dementia, were less likely to receive corticosteroids than those who were younger, as were pregnant women. This could reflect appropriate clinical decision making, but the possibility of inequitable access to life-saving care should be considered. FUNDING: UK National Institute for Health Research and UK Medical Research Council

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707